The drugs giant was criticised earlier this month for allegedly hiding negative trial results on the anti-depressant. Medicines regulator MHRA concluded GSK could not be sued, but the body's chief executive Kent Woods said the company had an ethical responsibility to share the data sooner.
The poll, by Opinion Matters, finds the vast majority of people - 96 per cent - agree with him. GSK's vice president, corporate media relations Philip Thomson said the company had tried to get some of the early data on the trials published in medical journals but it had ‘not been deemed of interest'.
But he acknowledged the strength of public feeling. ‘We were very disappointed with how the outcome of the investigation was portrayed,' he said. ‘GSK is genuinely making a difference to millions of patients' lives. Significant concerns around the availability of clinical trial
data have been raised and there is scope to improve guidance and legislation.'